Media stories about Hologic (NASDAQ:HOLX) have trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Hologic earned a news sentiment score of 0.22 on Accern’s scale. Accern also gave press coverage about the medical equipment provider an impact score of 46.2119134222111 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the news stories that may have impacted Accern Sentiment’s analysis:
- Namal Nawana Elected to Hologic Board of Directors (finance.yahoo.com)
- Gabelli Weighs in on Hologic, Inc.’s FY2018 Earnings (HOLX) (americanbankingnews.com)
- Contrasting Hologic (HOLX) and Illumina (ILMN) (americanbankingnews.com)
- Hologic Announces European CE Mark for Brevera Breast Biopsy System with CorLumina Imaging Technology (dotmed.com)
- Hologic Announces European CE Mark for Brevera® Breast Biopsy System with CorLumina® Imaging Technology (aboutpharma.com)
Shares of Hologic (HOLX) traded up $0.16 during midday trading on Friday, hitting $43.71. 3,060,000 shares of the stock were exchanged, compared to its average volume of 2,750,000. The firm has a market cap of $12,050.00, a P/E ratio of 16.56, a P/E/G ratio of 2.01 and a beta of 0.95. Hologic has a 1 year low of $35.76 and a 1 year high of $46.80. The company has a quick ratio of 0.61, a current ratio of 0.79 and a debt-to-equity ratio of 0.79.
Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.49 by $0.01. The firm had revenue of $802.90 million for the quarter, compared to the consensus estimate of $792.54 million. Hologic had a net margin of 24.70% and a return on equity of 21.69%. The company’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.52 EPS. sell-side analysts expect that Hologic will post 2.13 earnings per share for the current year.
HOLX has been the topic of several research reports. Royal Bank of Canada reaffirmed a “hold” rating and set a $42.00 price target on shares of Hologic in a report on Friday, September 22nd. Needham & Company LLC reaffirmed a “buy” rating and set a $50.00 price target on shares of Hologic in a report on Monday, October 2nd. Zacks Investment Research lowered shares of Hologic from a “hold” rating to a “sell” rating in a report on Tuesday, October 3rd. Stifel Nicolaus reissued a “buy” rating and set a $45.00 target price (down from $48.00) on shares of Hologic in a report on Monday, October 9th. Finally, Jefferies Group reissued a “buy” rating and set a $44.00 target price (down from $49.00) on shares of Hologic in a report on Tuesday, October 10th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. Hologic presently has an average rating of “Buy” and an average price target of $48.79.
In related news, Director Elaine Ullian sold 9,282 shares of the business’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $40.50, for a total transaction of $375,921.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Karleen Marie Oberton sold 1,023 shares of the business’s stock in a transaction on Monday, November 20th. The shares were sold at an average price of $39.84, for a total transaction of $40,756.32. The disclosure for this sale can be found here. Insiders have sold a total of 12,099 shares of company stock worth $487,223 in the last quarter. 0.79% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Hologic (NASDAQ:HOLX) Stock Price” was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://ledgergazette.com/2018/01/13/hologic-holx-receives-coverage-optimism-score-of-0-22.html.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.